For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Kinsale Capital Group Inc. (KNSL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Watch · Gem Score +39 (−100…+100 Quality+Value blend) · Quality 83 · Value 10 · Sentiment -45 (timing only, not weighted) · Composite fair value $743.83 vs $380.61 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Kinsale Capital Group Inc.
KNSL NYSEKinsale Capital Group Inc. is a specialty insurance provider focused on the excess and surplus lines market. This company offers insurance solutions to small businesses that often face challenges obtaining coverage through standard markets due to unique or high-risk characteristics. By specializing in hard-to-place risks, Kinsale Capital Group fills a vital niche in the insurance industry, addressing the needs of sectors such as construction, manufacturing, and professional services. The firm's comprehensive underwriting expertise and disciplined risk management help maintain its competitive edge. With its headquarters in Richmond, Virginia, Kinsale Capital Group plays a significant role in the diversified insurance services arena, meeting the evolving demands of businesses and contributing to financial stability within the market. This nimble approach allows it to adapt quickly to changing regulatory and economic landscapes, offering tailored products that reflect its customers' specific risk exposures.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 21.65
Total Equity: $1.96B
Shares: 23,261,617
Total Debt: $224.40M
Cash: $163.36M
EBITDA: N/A
Total Debt: $224.40M
Cash: $163.36M
Revenue: $1.87B
Revenue: $1.87B
Revenue: $1.87B
Total Equity: $1.96B
Tax Rate: 20.6%
Equity: $1.96B
Total Debt: $224.40M
Cash: $163.36M
Current Liabilities: N/A
Long-Term Debt: $224.40M
Total Debt: $224.40M
Total Equity: $1.96B
Shares: 23,261,617
Shares: 23,261,617
CapEx: -$53.69M
Shares: 23,261,617
Stock Price: $359.14
Net Income: $503.61M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 3, 2026 1:22pm (66d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $653.5M | $838.8M | $1.2B | $1.6B | $1.9B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $669,000 | $721,000 | $942,000 | $4.0M | $1.7M |
| Operating Income | — | — | — | — | — |
| Net Income | $152.7M | $159.1M | $308.1M | $414.8M | $503.6M |
| EBITDA | — | — | — | — | — |
| EPS | $6.73 | $6.97 | $13.37 | $17.92 | $21.76 |
| EPS (Diluted) | $6.62 | $6.88 | $13.22 | $17.78 | $21.65 |
Balance Sheet (Annual)
Last updated: Aug 3, 2026 12:56pm (66d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $121.0M | $156.3M | $126.7M | $113.2M | $163.4M |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $2.0B | $2.7B | $3.8B | $4.9B | $6.0B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $42.7M | $195.7M | $183.8M | $184.1M | $224.4M |
| Total Liabilities | $1.3B | $2.0B | $2.7B | $3.4B | $4.1B |
| Total Equity | $699.3M | $745.4M | $1.1B | $1.5B | $2.0B |
| Retained Earnings | $385.9M | $533.1M | $828.2M | $1.2B | $1.7B |
Cash Flow (Annual)
Last updated: Aug 3, 2026 1:22pm (66d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $407.0M | $557.8M | $859.8M | $976.3M | $1.0B |
| Capital Expenditure | -$5.9M | -$6.9M | -$6.6M | -$23.9M | -$53.7M |
| Free Cash Flow | $401.1M | $550.9M | $853.2M | $952.4M | $990.1M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | $0 | $125.0M | $50.0M | $0 | $0 |
| Dividends Paid | -$10.0M | -$11.9M | -$13.0M | -$13.9M | -$15.8M |
| Stock Buybacks | — | $0 | $0 | -$10.0M | -$90.0M |
| Net Change in Cash | — | — | — | — | — |
Growth Trends (YoY %)
Last updated: Aug 3, 2026 1:22pm (66d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +28.4% | +46.0% | +29.7% | +18.0% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | +4.2% | +93.6% | +34.6% | +21.4% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Aug 3, 2026 12:56pm (66d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-28 | $0.25 | — | — | — |
| 2026-02-26 | $0.25 | — | — | — |
| 2025-11-28 | $0.17 | — | — | — |
| 2025-08-29 | $0.17 | — | — | — |
| 2025-05-29 | $0.17 | — | — | — |
| 2025-02-27 | $0.17 | — | — | — |
| 2024-11-29 | $0.15 | — | — | — |
| 2024-08-29 | $0.15 | — | — | — |
| 2024-05-31 | $0.15 | — | — | — |
| 2024-02-26 | $0.15 | — | — | — |
| 2023-11-28 | $0.14 | — | — | — |
| 2023-08-28 | $0.14 | — | — | — |
| 2023-05-30 | $0.14 | — | — | — |
| 2023-02-27 | $0.14 | — | — | — |
| 2022-11-29 | $0.13 | — | — | — |
| 2022-08-26 | $0.13 | — | — | — |
| 2022-05-27 | $0.13 | — | — | — |
| 2022-03-01 | $0.13 | — | — | — |
| 2021-11-26 | $0.11 | — | — | — |
| 2021-08-30 | $0.11 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-05 02:02A +1σ run of quarters pays +60%; a −1σ run costs 17%. Ratio 3.6:1 (μ 20.5%, σ 11.1% , 16 pairs).
Older method (repeat-worst-quarter): 3.0 : 1
| Case | Growth | Margin | Fair value | vs price ($380.61) |
|---|---|---|---|---|
| Bull — recovery | +23% | 32.8% | $547.94 | +44% |
| Base — stabilizes | +16% | 28.5% | $382.93 | +1% |
| Bear — keeps slipping | +8% | 24.2% | $260.89 | -31% |
| Stress — last quarter repeats | +10% | 28.5% | $325.11 | -15% |
| Upside — a +1σ run of quarters (v2) | +32% | 28.5% | $607.73 | +60% |
| Stress — a −1σ run of quarters (v2) | +9% | 28.5% | $316.70 | -17% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-29 00:55The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw quarterly tape tells a more interesting story than any of the models grabbed onto. Revenue jumped from $423M in Q1'25 to $498M in Q3'25, then *dropped* to $483M in Q4'25 and cratered to $467M in Q1'26 before spiking to $549M in Q2'26 with a suspicious 32.1% net margin — well above the 26-28% band that had been the norm. That Q2'26 print is doing a lot of heavy lifting: strip it out and you have a business that decelerated meaningfully through late 2025 and stalled in early 2026. The recent YoY revenue growth of 18% is already half the 5-year CAGR of ~30% (rev went from $653M in 2021 to $1.87B in 2025), and the Q1'26 24.1% margin is the second-lowest print in the series. This is a business visibly transitioning from hypergrowth-in-a-hard-market to something more mundane, exactly as the bear narrative suggests.
The synthesis verdict of $722 fair value (+119%) is, frankly, absurd for a P&C insurer and I'd throw it out. At $380, KNSL trades at 17.5x earnings, 4.5x book, and ~4.7x sales — those are premium multiples for an insurer, not distressed ones. Progressive trades around 4x book, Chubb around 1.9x, W.R. Berkley around 2.7x. KNSL's 25.7% ROE justifies a premium, but the whole question is whether that ROE is structural or a hard-market artifact. If normalized ROE reverts to 18-20% (still excellent), a 3.0-3.5x book multiple gets you $300-350, not $722. The DCF-driven composite is almost certainly extrapolating peak-cycle FCF and premium growth into perpetuity — the FCF CAGR of only 7.7% versus earnings CAGR of 27.9% is itself a red flag that reported earnings have outrun cash generation, consistent with Market Forces' 2.34x accrual ratio callout, which the synthesis conveniently ignored.
The models contradict each other in ways worth naming. Pre-flight says "peak hard market conditions" concern is legitimate; Market Narrative says the discount is "rational repricing of cyclical underwriting conditions"; Market Forces flags accrual quality and limited margin of safety — yet Synthesis still lands on undervalued by 119%. You cannot simultaneously believe the cycle is normalizing AND that fair value is nearly 2.2x current price unless you're double-counting. The Narrative layer is actually the most honest here: it explicitly says narrative premium/discount is muted and the gap is cycle repricing. That's the right frame. Insurance reserves are also a black box — the accrual ratio suggests either reserve releases juicing earnings or growing IBNR that will bite later; without loss ratio and combined ratio disclosure in this data pack, we're flying blind on the single most important metric for a specialty insurer.
The contrarian argument the models missed: KNSL's E&S niche has been the beneficiary of standard-market dislocation (wildfire exposure, social inflation, admitted-market pullback). When standard carriers return — and they always do once rates harden their books — the submission flow that made Kinsale's expense ratio (~20% vs. industry 30%+) so devastatingly effective compresses. The Q1'26 margin dip may be the first tremor. I'd want to see two more quarters of combined ratio data before believing either the bull or bear case, but at $380 with visible deceleration, no margin of safety, and premium multiples, the risk/reward is not compelling. Fair value is closer to $320-360 on a normalized 20% ROE and 3.2x book; the $722 synthesis number is fantasy. I dissent from the "undervalued +119%" verdict emphatically, and lean modestly bearish on valuation, not on business quality — this remains a best-in-class underwriter, just not one worth chasing here.
GPT Reading
Kinsale’s numbers still read like an elite P&C underwriter, not a business in visible deterioration. Revenue went from $653.5M in 2021 to $1.87B in 2025, a near tripling in four years, while net income rose from $152.7M to $503.6M. That is not just premium growth bought with sloppy underwriting; net margin expanded from roughly 23% in 2021 to 26.9% in 2025, and the latest four quarters are even stronger. On a trailing basis from 3Q25 through 2Q26, revenue is about $2.0B and net income about $568.7M, implying a trailing net margin around 28.4%. Quarterly earnings are lumpy, but the direction is favorable: 2Q26 revenue of $548.5M was up 16.7% from $469.8M a year earlier, while net income jumped 31% to $175.9M and margin hit 32.1%. For an insurer with only $224.4M of debt against $1.96B of equity, 25.7% ROE is exceptional. This is a capital-light compounding machine by insurance standards.
What stands out most is the disconnect between that operating quality and the valuation being discussed by the models. I do not buy the idea that this is worth anything like $700-$800 per share based on the data provided. At $380, the stock already trades at 17.6x earnings, 4.5x book, and 4.7x sales. For most insurers, 4.5x book would be absurd; Kinsale earns a premium because it deserves one, but the multiple already assumes that today’s profitability is structurally superior, not merely cyclical. Using the 2025 net income of $503.6M, the market cap implies that 17x-18x earnings multiple; on the more favorable trailing earnings run-rate of $568.7M, it drops to about 15.3x. That is reasonable for a best-in-class franchise, but not a screaming bargain when the business sits in a cyclical E&S market. The rule-based “mature earner” label is too conservative on growth, yet the huge undervaluation call swings too far the other way by capitalizing recent results as if the margin structure is immune to market softening. My read is simpler: this is a very good company at a price that roughly reflects that fact.
The cash flow line needs careful interpretation. Reported operating cash flow of $1.04B and free cash flow of $990.1M against $503.6M of net income looks phenomenal, but for insurers, cash generation can be heavily affected by premium float and reserve movements, so I would not treat that like industrial-style free cash flow. The more reliable quality markers here are sustained earnings growth, low leverage, and high ROE. Book equity of $1.96B against a market cap of $8.7B means investors are paying dearly for underwriting skill, and that can be justified if Kinsale keeps compounding book value at high rates. But when a stock already discounts durable mid-20s ROE, the upside from “it remains excellent” is much smaller than the downside from “it normalizes to merely good.” That is why I land closer to fairly valued than undervalued despite admiring the franchise.
The strongest argument against my caution is straightforward: the business may be better than I am allowing for, and the recent numbers support that. Revenue reaccelerated from $423.4M in 1Q25 to $548.5M in 2Q26, and quarterly margins moved from 21.1% in 1Q25 to 32.1% in 2Q26. If Kinsale is proving it can keep growing high teens while expanding margins even as others worry about softening conditions, then a premium multiple is not only justified but perhaps still too low. A trailing P/E near 15x for a company growing revenue 18% and earnings 21% with virtually no balance-sheet stress is not expensive in absolute terms. Bulls can also point out that even if book multiple compresses, retained earnings are compounding fast enough to offset part of that. In other words, if Kinsale’s underwriting edge is structural, not just hard-market luck, then my insistence on cyclical normalization will look too conservative.
What would change my mind is not another abstract DCF, but evidence on durability. If the next few quarters show revenue growth holding above 15% while net margins stay in the high-20s and book value continues compounding without reserve or catastrophe surprises, then I would be willing to underwrite a higher fair value, likely north of $425. Conversely, if growth slows toward low double digits and margins slip back toward the low-20s range seen in 1Q25, the current 4.5x book will look rich and I would move clearly negative below that operating threshold. At $380, I see a first-rate insurer priced like one: attractive on quality, not obviously mispriced on value.
Grok Reading
Kinsale’s numbers still read like a high-quality specialty underwriter that has not yet rolled over. Revenue scaled from $653.5M in 2021 to $1.87B in 2025, with net income rising from $152.7M to $503.6M; the latest quarter (2026-06-30) printed $548.5M revenue and $175.9M net income at a 32.1% margin, well above the mid-20s run rate of the prior year. Trailing four-quarter net income is roughly $569M against an $8.7B market cap, so the stock is paying about 15–16× current earnings power and 17.6× on the stated annual PE—hardly a bubble multiple for a firm still delivering 18% revenue growth and 21% earnings growth year-over-year, 25.7% ROE, net margin near 27%, and a fortress balance sheet ($224M debt against $1.96B equity, D/E 0.11). Operating cash flow of $1.04B and FCF of $990M on $504M of annual NI confirm that reported profits are converting, which matters more for an E&S carrier living on float and reserve adequacy than a simple industrial accrual screen. The story the tape is telling—a fallen-angel de-rating on hard-market normalization—is running ahead of the income statement; margins and top-line growth have not cracked.
Where the quantitative composite goes wrong is the leap to $722–$834 fair value (+119%). That embeds a permanence of 25%+ ROE and mid-teens premium growth that E&S history does not support once standard markets reopen and rate adequacy softens. A more grounded cross-check is simpler: $570M trailing NI growing high-single to low-double digits into a mid-cycle ROE of 18–20% justifies something closer to 18–20× earnings and ~3.5–4.0× book, i.e. a $450–$520 zone, not a double. PB at 4.52× already prices a long runway of excess returns; if combined ratios normalize and growth settles near the 7.7% FCF CAGR rather than the 24–28% revenue/earnings CAGRs of the hard-market years, that multiple compresses. Secondary flags are real: revenue confidence is labeled decelerating, macro headwinds sit over the sector, and a 2.34× accrual ratio is the one earnings-quality blemish that keeps this from being a clean compounder at any price. The dividend is a rounding error (0.22% yield, 3% payout), so the entire thesis is total-return compounding off underwriting, not income.
The strongest opposing case is cycle mean-reversion dressed up as valuation discipline. Skeptics will correctly note that Kinsale’s 23.7% revenue and 27.9% earnings CAGRs were earned in a historic hard market; as admitted carriers claw back E&S business, premium pools shrink and price competition returns, the 28–32% net margins of recent quarters are the peak, not the floor. They will cite the FCF CAGR of only 7.7% as the truer run-rate of economic profit once reserve releases and unearned-premium tailwinds fade, and they will argue that 4.5× book with only a thin margin of safety into a soft market is how specialty insurers permanently re-rate lower—exactly the bear narrative already in the tape. The Market Forces “neutral” tag and the explicit warning on earnings quality and limited margin of safety are the cleanest quantitative expression of that view. I weigh it as the right risk factor but the wrong current price conclusion: the income statement has not yet validated the soft-market haircut the multiple already embeds, and cash generation plus low leverage give the franchise time to prove underwriting discipline through the turn. Paying 17× for still-accelerating quarterly NI of $176M while the composite models scream 100%+ upside is not the same as ignoring cycle risk; it is refusing to double-count a slowdown that is priced but not yet printed.
What flips me is straightforward and near-term. Two consecutive quarters of revenue growth inside 10% with net margin compressing through 22%, or a combined-ratio print that shows reserve strengthening rather than release, and the $380 handle becomes fair to rich toward the mid-$300s. Conversely, another two quarters that hold ~15%+ top-line growth and margins above 25% into 2027, with ROE staying north of 22% while the E&S rate environment only modestly softens, and the stock earns a re-rating toward $480–$520 and my stance moves from modestly undervalued to clearly so. Catastrophe loss spikes or a material uptick in debt-funded capital return would also break the fortress-balance-sheet half of the thesis immediately.
Qwen Reading local experiment · off-panel
The number that should make you pause before you dismiss the 16.6x P/E as "cheap insurance" is the 25.7% ROE sustained alongside an 8.33% ROA and a debt-to-equity ratio of 0.11. That combination — generating a quarter of its book value in profit annually with essentially no leverage — is not a cyclical artifact; it is the structural signature of a business that has found a pricing niche (excess and surplus lines) where standard-market carriers won't compete. Revenue has compounded from $653.5M in 2021 to $1.87B in 2025, a 28% CAGR, and net income has more than tripled over the same span to $503.6M. At $359.14, you are paying $8.12B for a company that threw off $1.04B in operating cash flow last year and $990M in free cash flow, with capex of a trivial $53.7M. The P/S of 4.46x looks rich in a vacuum, but against a 26.9% net margin and a 25.7% ROE, it is actually the cheapest way to buy that quality of earnings in the P&C space. The prior model's $841.88 composite fair value is, frankly, a category error — it is applying growth-stock DCF mechanics to an insurance float model where the "free cash flow" line is distorted by premium collection timing and reserve releases. I would not anchor to that number. But I also would not anchor to the 16.6x P/E as if it were a mean-reversion trade, because the earnings base is still expanding at 20%+ and the ROE is not a peak-cycle blip; it has been in the 20-28% range for multiple years.
What genuinely concerns me is the sequential margin step-down. Q4 2025 printed a 28.7% net margin on $483.3M of revenue; Q1 2026 came in at 24.1% on $466.7M. That is a 460-basis-point compression in one quarter, and while Q1 is seasonally softer for insurers, the YoY comparison (Q1 2025 was 21.1%) means the improvement is real but the sequential deterioration is a leading indicator that the E&S hard market is beginning to soften. Revenue growth has also decelerated: the 23.7% four-year CAGR has given way to roughly 10% YoY in the most recent quarter ($466.7M vs. $423.4M). The FCF CAGR of 7.7% versus the revenue CAGR of 23.7% is the single most uncomfortable data point in this file. For a non-insurance company that would signal a business model that consumes cash as it scales. For an insurer it is more likely a timing artifact — claims development lags premium collection, and reserve strengthening in a softening market hits operating cash flow before it hits the income statement. But I cannot wave it away entirely. If the E&S market normalizes over the next two to three years, the 28%+ margins that have defined Kinsale's 2023-2025 print will compress toward the 20-22% range, and the 20%+ revenue growth will likely decelerate toward 8-12%. That is still a great business, but it is not the 25%-ROE, 20%-growth machine the trailing numbers describe.
The insider tape is a small but telling negative that the "Net Insider Buying" label obscures. The only actual purchase in the last ten transactions is 330 shares on June 8 — rounding error. The pattern in early May is option exercises of 22,576 and 600 shares followed by sales of 21,778 and 250 shares, which is a textbook cash-out of vested options, not conviction buying. Then there are two gift transactions totaling roughly 27,865 shares, which is estate planning or family transfer, not a signal. No one at Kinsale is writing a check to tell the market they believe the stock is cheap. That is not damning, but it removes one of the secondary signals the prior model leaned on.
The strongest case against my undervalued read is the cycle argument, and I take it seriously. Specialty P&C is not a structural-growth story in the way a software company is; it is a pricing story. The E&S market has been in a hard cycle since roughly 2021, and Kinsale's 28%+ net margins are the direct product of that hardening. When the cycle turns — and it always turns — loss ratios will creep up, premium growth will slow as competitors re-enter niches they abandoned, and the 25.7% ROE will compress. A smart bear would point to the 4.26x P/B and argue that at 25% ROE the market is already paying a quality premium, and that if ROE normalizes to 15-18% (still excellent, but not Kinsale's 2023-2025 print), the P/B should compress to 3x or below, implying a share price in the $250-$290 range. I weigh this risk, but I discount it for two reasons: first, the E&S niche is structurally less competitive than standard P&C because the carriers serving it are smaller, less diversified, and less able to absorb rate pressure, which means the pricing floor is higher; second, Kinsale's balance sheet (total equity of $1.96B against $224.4M of debt) gives it the option value to buy market share in a soft market rather than being forced to cede it. The 0.11 debt-to-equity ratio is not just a comfort metric; it is a strategic weapon in a cyclical industry.
What would change my mind in either direction. On the bear side: if Q2 2026 (reporting around late July) shows net margin below 22% and revenue growth below 8% YoY, the "deceleration" I am flagging in Q1 becomes a trend, and I would downgrade to fairly valued or below, because the 16.6x P/E would then be pricing in a growth rate that is no longer materializing. On the bull side: if Q2 shows margin holding above 26% and revenue growth re-accelerating above 15%, that would confirm the Q1 dip was seasonal noise, and I would push my fair value range higher, toward $500-$550, because the market would be forced to re-underwrite the sustainability of the ROE. A dividend initiation or a meaningful buyback announcement would also shift the calculus, since the current 0.23% yield and 3.1% payout ratio tell me management is reinvesting aggressively, which is the right call at 25% ROE but leaves the stock without a yield floor for income-oriented holders.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue nearly tripled from $653.5M in 2021 to $1.87B in 2025 (roughly 30% CAGR) while net income more than tripled from $152.7M to $503.6M, indicating operating leverage and improving underwriting economics rather than growth bought with capital. FCF scaled from $401M to $990M with OCF/NI at 2.68x and accruals at -12.4% of assets - earnings are backed by cash, which is unusual quality for a P&C insurer where reserve accounting can flatter earnings. Diluted share count barely moved (23.1M to 23.3M, 0.2% CAGR) with SBC at only 1% of revenue and buybacks running 189% of SBC, so per-share value is being protected, not diluted. Net debt of -$61M against $990M FCF is trivial; the business self-funds its growth. Altman Z at 1.99 (grey) is a rating-model artifact for a financial and not a meaningful distress signal here. The overall picture is a disciplined, high-return E and S specialty underwriter compounding book value with unusual capital discipline.
Verify before trusting this (5)
- Prior-year loss reserve development trend in the 10-K to confirm reserves are not being released to flatter earnings
- Catastrophe and reinsurance program structure, including net retention and any aggregate cover changes
- Combined ratio and expense ratio trajectory, and any premium concentration by line or geography
- Investment portfolio composition and unrealized loss position given rate environment
- Insider selling cadence relative to grants to confirm the buyback vs SBC math
The e2e composite fair value of $722 and signal-adjusted $834 imply 90-119% upside, but that is almost entirely driven by a DCF at $898 that appears to extrapolate hard-market growth and margins far into the future - I discount it heavily. The anchored-PE output of $370 is essentially in line with the $380.61 price, which tells me on a normalized-earnings multiple the stock is already fair. Splitting the difference and giving credit for Fortress-grade quality (score 83), high earnings quality, and near-zero dilution, my deserved value sits around $450-$500 - roughly 20-30% above spot. That is a genuine but not screaming discount. What is priced in: some deceleration from hard-market peaks, competitive re-entry from standard carriers, and CAT uncertainty - the fallen-angel narrative. What is NOT priced in: continued share-gain in E and S, sustained mid-20s ROEs, and the compounding optionality of a disciplined underwriter with real broker moat. The gap exists because the market is extrapolating cyclical normalization onto a structurally advantaged franchise. It is not a fat pitch - I would want $320 or lower to swing hard - but at $380 it is not expensive either.
Verify before trusting this (4)
- Q-over-Q gross written premium growth and any submission-flow commentary indicating E and S market share
- Combined ratio trend and any adverse or favorable reserve development disclosures
- Management commentary on rate adequacy and competitive re-entry from standard carriers
- Investment portfolio yield and duration positioning as rates move
The macro tape is modestly risk-on (VIX 14, S&P near highs) which is a light tailwind, but KNSL's 0.89 beta means it barely amplifies the move either way. The active narrative is a fallen-angel: the market has already re-rated the stock lower on fears of E&S premium pool shrinkage, softening rate environment, and CAT uncertainty. Intensity and durability are only moderate and cult is low, so the negative story is not accelerating - but it is not resolved either, which caps upside pressure. Peer news flow is unhelpful: ACGL down 3.7% and CINF down 6.1% post-earnings, with TRV touting AI underwriting advantages - all reinforcing the 'P&C is out of favor' subtext that lands directly on KNSL as a specialty carrier. Momentum decelerating (18% recent vs 23.7% long-term) confirms the tape is fading rather than accumulating this name. Net: no dominant force in either direction, mild sector headwind roughly offsets the calm-tape tailwind.
Verify before trusting this (4)
- Next KNSL earnings print - combined ratio and premium growth trajectory will either break or confirm the fallen-angel narrative
- Hurricane season CAT developments through Q3/Q4 - a benign season would relieve reserve-adequacy fears
- Analyst target revisions post-peer earnings - watch for downgrades cascading from ACGL/CINF weakness
- Any sign of E&S rate stabilization data (Council of Insurance Agents quarterly) that would puncture the softening-market bear thesis
The world is moving from a hard E&S market — where price alone delivered growth — to a normalizing one where growth must come from share and product breadth. That transition favors the lowest-cost underwriter with owned distribution economics, which is Kinsale's exact shape, but it removes the free rate tailwind that made 24% CAGRs look easy. High rates (10y 4.67%) are a genuine offset: they convert premium growth into investment income at attractive new-money yields, which is why earnings growth (+29%) is running well ahead of revenue growth. Macro headwinds and a slowing sector cycle argue for deceleration, not contraction.
When we made this prediction on Aug 29, 2026, KNSL was $380.61. We expect it to be $455.00 by Mar 2027, and we consider it great value under $320.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 29, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.